DENDRITIC NANOTECHNOLOGIES Signs Collaboration Agreement With Nanotechnology Characterization Laboratory

    MOUNT PLEASANT, Mich., Oct. 10 /PRNewswire/ -- DENDRITIC NANOTECHNOLOGIES
 INC. (DNT), a company that is focused on the discovery, development, and
 commercialization of dendrimer technologies to create a new generation of
 innovative products for the identification and treatment of human diseases,
 has entered into one of the first characterization collaborations with the
 Nanotechnology Characterization Laboratory (NCL), an organization established
 by the National Cancer Institute to foster collaboration between the
 government and the private sector. The agreement with NCL will focus on the
 characterization by NCL of DNT's STARBURST(TM) dendrimers as macromolecular
 dendrimer-based MRI contrast agents for sensitive, non-invasive cardiovascular
 diagnostics.
     DNT's STARBURST and Priostar(TM) dendrimers are "smart" biopharmaceutical
 nanotechnology platforms that can be used to deliver precise quantities of a
 drug or contrast agent to a specific location within the human body. DNT's
 dendrimers will be subjected to an assay cascade consisting of physical
 characterization, in vitro studies, and in vivo ADME/Tox protocols to
 determine their absorption, distribution, metabolism, excretion, and toxicity.
 DNT's proprietary dendrimer platform also serves as a targeted diagnostic and
 therapeutic delivery system for a wide variety of drugs to cancer cells and
 other diseases. Improved efficacy, enhanced solubility, and lower toxicity
 have been demonstrated for many existing drugs.
     The intent of these studies is to generate data in support of an
 investigative new drug (IND) filing with the U.S. Food and Drug Agency (FDA).
 It is estimated that the NCL's characterization efforts will take
 approximately 12-15 months.
     "Development of dendrimer-based MRI contrast agents for sensitive, non-
 invasive intravascular agents is highly desired in the medical world," said
 Robert Berry, DNT's chief executive officer. "DNT's STARBURST dendrimers have
 demonstrated intravascular properties that increase sensitivity and image
 clarity with potentially lower dosage compared to currently available general-
 use contrast agents. DNT's smart nanostructures feature precise and
 predictable physical properties that make them especially useful in commercial
 applications requiring novel properties with nanometer precision."
     The collaboration agreement with DNT is one of the first characterization
 agreements entered into by the NCL and will be used to perform a preclinical
 assessment of DNT's intravascular dendrimer-based MRI contrast agents. These
 assessments will help provide the data necessary to enter the FDA's Phase I
 clinical trials. This will be the second dendrimer-based application submitted
 to FDA:  Starpharma Holdings Ltd. (a DNT license holder and investor) is
 currently entering Phase II clinical trials with a dendrimer-based topical
 microbicide, VivaGel(TM), aimed at the prevention of HIV.
     In 2005, the National Institute of Standards and Technology, the Food and
 Drug Administration, and the National Cancer Institute established the
 Nanotechnology Characterization Laboratory to perform preclinical efficacy and
 toxicity testing of nanoscale materials. A key activity of the NCL will be to
 work with FDA scientists to develop an assay cascade that can serve as the
 standard protocol for preclinical toxicology, pharmacology, and efficacy of
 nanoscale materials. This assay cascade will characterize a nanoscale device's
 physical attributes, its in vitro biological properties, and its in vivo
 compatibility.
 
     Dendrimers -- an Emerging Platform for New Diagnostics
     The versatility of the dendrimer architecture provides DNT and its
 commercial partners with unique advantages. The ability to control the
 properties of size, surface, and encapsulation are critical to any
 intravascular agent product. Feasibility studies on dendrimer-based contrast
 agents have demonstrated excellent carrying capacity, superior image
 enhancement, and sufficient retention for imaging, with good routes of
 elimination. The use of dendrimers as a platform for new therapies has already
 yielded excellent results:  DNT has encapsulated Magnevist(R), AG Schering's
 off-patent, low molecular weight, market-leading contrast agent, within its
 STARBURST and Priostar dendrimers. DNT's technology has allowed Magnevist
 molecules to be contained within the dendrimer interior, resulting in the
 creation of a macromolecular contrast agent with the surface available for
 further modification.
 
     About the Nanotechnology Characterization Laboratory
     The Nanotechnology Characterization Laboratory (NCL) performs and
 standardizes the pre-clinical characterization of nanomaterials intended for
 cancer therapeutics and diagnostics developed by researchers from academia,
 government, and industry. The NCL serves as a national resource and knowledge
 base for cancer researchers, and facilitates the development and translation
 of nanoscale particles and devices for clinical applications.
     The National Cancer Institute believes that the NCL's activities will
 markedly speed the development of nanotechnology-based products for cancer
 patients, reduce the risk of doing so, and encourage private-sector investment
 in this promising area of technology development. By achieving its goals, the
 NCL will provide a comprehensive set of baseline characterization parameters
 that will enable cancer biologists, drug and diagnostic developers, and
 clinical oncologists to apply their tools to solving problems that most affect
 cancer patients. This work will also lay a scientific foundation that will
 enable the FDA to make sound decisions concerning the testing and approval of
 nanoscale cancer diagnostics, imaging agents, and therapeutics. See
 http://ncl.cancer.gov .
 
     About DNT
     DENDRITIC NANOTECHNOLOGIES INC. (DNT) is focused on the discovery,
 development, and commercialization of dendrimer technologies to create a new
 generation of innovative products for the identification and treatment of
 human diseases. DNT's proprietary dendrimer platform serves as a targeted
 diagnostic and therapeutic delivery system for a wide variety of drugs to
 cancer cells and other diseases. Improved efficacy, enhanced solubility, and
 lower toxicity have been demonstrated for many existing drugs.
     DNT is committed to producing commercially viable dendrimers that can be
 manufactured in large quantities, and to driving down manufacturing complexity
 and costs. The company has a patent pending on its Priostar(TM) family of
 dendrimers, a novel dendrimer family that breaks through previous cost and
 manufacturing barriers.
     DNT's technology development is directed by Donald A. Tomalia, Ph.D.,
 president and chief technical officer. Dr. Tomalia is the inventor of
 dendrimers and has led numerous commercial developments during a 25-year
 management and senior scientist career with The Dow Chemical Company.
     DNT is committed to developing and integrating dendrimer technologies via
 corporate alliances that allow DNT scientists to use their combined expertise
 to assist business partners by accelerating the pre-clinical development of
 products that are significantly more effective and safer.
     See http://www.dnanotech.com .
     Starpharma (ASX:SPL) is an equity holder in DNT and is focused on the
 development and application of dendrimer nanotechnologies as drugs against
 major diseases. Starpharma's lead dendrimer product, VivaGel(TM) is currently
 in U.S. FDA Phase II human clinical trials. VivaGel is a topical microbicide
 gel product that has been developed for women as a preventative against the
 sexual transmission of HIV.
 
     NOTE:  STARBURST and Priostar are trademarks of DENDRITIC NANOTECHNOLOGIES
 INC. All other trademarks mentioned herein are held by their respective
 owners.
 
 

SOURCE DENDRITIC NANOTECHNOLOGIES INC.

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.